
Oncology studies present specific challenges that generate complex eCOA build and management: complex study design, frequent amendments, and long study duration that can affect patient engagement and site organization.

To overcome these challenges, Kayentis offers strong and global experience in complex oncology trials, especially with:

experienced teams and strong processes to face trial complexities and amendments,

a large set of data collection modes for an optimal data entry,

additional features for the comfort of the patient,

and functionalities adapted to support site staff,

Kayentis contributes to the success and quality of oncology clinical trials.


Learn more in the case study:

ONCOLOGY CASE STUDY

Kayentis

offers global experience in complex oncology trials

- **65+** studies, 14,000+ patients, 5,000+ sites
- **Large programs**
 - ✓ 90% Global Phase II/III trials across patient populations
 - ✓ 10 to 45 countries per study, worldwide
 - ✓ **Long term studies:** up to 8 years
- **Extensive experience**, including:
 - ✓ CAR-T cell treatment developments
 - ✓ Many indications:
 - ALL, AML, CML, Large B-cell lymphocytic leukemia
 - Follicular lymphoma, myelodysplastic syndrome, multiple myeloma
 - Renal carcinoma, lung, breast, prostate, pancreas, thyroid cancer
 - MTC, Melanoma



ePRO, eClinRO, eObsRO and eDiary assessment:

Many ePROs used to assess disease-related symptoms (eg, pain, fatigue) as well as physical, social & emotional aspects, satisfaction survey:

- **EORTC:** QLQ-C30, QLQ-C31, QLQ-LC13, QLQ-MY20, QLQ-BR23, IL-134, IL-46
- **FACT Fatigue:** FACT-M, FACT-BR, Fact-P, FACT-G, FACT-BMT, FACT -GP5
- **EuroQoL:** EQ-5D 3L/EQ-5D Youth, EQ-5D 5L, PedsQL, young adult & adolescent
- PROMIS-29, PROMIS PSF, PROMIS Parnt Proxy 7
- PRO-CTCAE, MDASI, NSCLC SAQ, PGI-C, PGI-I, PGI-S, NCCN NFBrsI-24

Download the case study



Contact us for more information

Key Words:

- eCOA
- ePRO
- eDiary
- oncology
- clinical trial

[Learn more:](#)



The strengths of electronic Clinical Outcome Assessment (eCOA) versus paper solutions

5 February 2024

In contrast to paper solutions, electronic Clinical Outcome Assessment (eCOA) demonstrates strengths such as: Accuracy

[Read More »](#)



The relevance of ePROs in early phase clinical trials

31 January 2024

Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the

[Read More »](#)



3 considerations to take into account when setting up an eCOA clinical trial

29 January 2024

In a clinical trials environment that is moving increasingly towards digitalization and decentralization, it remains

[Read More »](#)



Kayentis operational excellence

23 January 2024

Why do customers recommend Kayentis for operational excellence? More than 95% of Kayentis customers recommend

[Read More »](#)



Innovation and Partnerships: The Biotech Perspective

16 January 2024

In the ever-evolving landscape of biotechnology, groundbreaking advancements continue to shape the future of healthcare.

[Read More »](#)



Exploring The Specific Challenges Of Pediatric Clinical Trials – Insights From Site Experts

22 November 2023

In this first episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)